Japan Amyloidosis Treatment Market Size & Outlook
Related Markets
Japan amyloidosis treatment market highlights
- The Japan amyloidosis treatment market generated a revenue of USD 1,101.3 million in 2021 and is expected to reach USD 1,637.0 million by 2028.
- The Japan market is expected to grow at a CAGR of 5.8% from 2022 to 2028.
- In terms of segment, al was the largest revenue generating type in 2021.
- ATTR is the most lucrative type segment registering the fastest growth during the forecast period.
Amyloidosis treatment market data book summary
| Market revenue in 2021 | USD 1,101.3 million |
| Market revenue in 2028 | USD 1,637.0 million |
| Growth rate | 5.8% (CAGR from 2021 to 2028) |
| Largest segment | Al |
| Fastest growing segment | ATTR |
| Historical data | 2018 - 2020 |
| Base year | 2021 |
| Forecast period | 2022 - 2028 |
| Quantitative units | Revenue in USD million |
| Market segmentation | AL, AA, ATTR |
| Key market players worldwide | Pfizer Inc, Ionis Pharmaceuticals Inc, Takeda Pharmaceutical Co Ltd, Johnson & Johnson, Alnylam Pharmaceuticals Inc |
Other key industry trends
- In terms of revenue, Japan accounted for 11.3% of the global amyloidosis treatment market in 2021.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2028.
- In Asia Pacific, Japan amyloidosis treatment market is projected to lead the regional market in terms of revenue in 2028.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 445.7 million by 2028.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Amyloidosis Treatment Market Scope
Amyloidosis Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Alnylam Pharmaceuticals Inc | View profile | 2100 | 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, United States, 02142 | https://www.alnylam.com |
| Ionis Pharmaceuticals Inc | View profile | 927 | 2855 Gazelle Court, Carlsbad, CA, United States, 92010 | https://www.ionispharma.com |
| Takeda Pharmaceutical Co Ltd | View profile | 49095 | 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668 | https://www.takeda.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| Johnson & Johnson | View profile | 134400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | https://www.jnj.com |
Japan amyloidosis treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to amyloidosis treatment market will help companies and investors design strategic landscapes.
Al was the largest segment with a revenue share of 44.13% in 2021. Horizon Databook has segmented the Japan amyloidosis treatment market based on al, aa, attr covering the revenue growth of each sub-segment from 2018 to 2028.
Reasons to subscribe to Japan amyloidosis treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Japan amyloidosis treatment market databook
-
Our clientele includes a mix of amyloidosis treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan amyloidosis treatment market , including forecasts for subscribers. This country databook contains high-level insights into Japan amyloidosis treatment market from 2018 to 2028, including revenue numbers, major trends, and company profiles.
Partial client list
Japan amyloidosis treatment market size, by therapy, 2018-2028 (US$M)
Japan Amyloidosis Treatment Market Outlook Share, 2021 & 2028 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
